HRA Pharma Expands Footprint With Middle East Move

France's HRA is looking to tap into consumer demand for foot care products in the Middle East by rolling out its Compeed brand in select markets across the region.

Physical map of Middle East with scale. Elements of this image furnished by NASA
• Source: Shutterstock

HRA Pharma SA is poised to take its first steps into the Middle East as the company pushes ahead with plans to more than double its sales by 2022.

The Paris-based firm will launch its Compeed blister and scar-care brand in the United Arab Emirates and Kuwait in January...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Reckitt Strikes Deal To Sell Essential Home Unit To Focus On CHC, Hygiene

 
• By 

Advent International is poised to take control of Reckitt's Essential Home business, but the UK-based firm will retain a 30% stake.

People On The Move: Appointments At Opella, Stada, Futura

 
• By 

Latest European appointments: Opella names Germany director; Stada has new Western Europe head; Futura makes CEO change.

Perrigo Implements Streamlining Plan With Sale Of Dermacosmetics

 
• By 

Perrigo stands to gain up to €327m with sale of brands such as ACO and Emolium to KKR.

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

More from Business

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By 

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.